公开(公告)号：US12102713B2

公开(公告)日：2024-10-01

申请号：US17903597

申请日：2022-09-06

申请人： NOF CORPORATION ,  KINKI UNIVERSITY

发明人： Noriaki Nagai ,  Shunsuke Sakurai ,  Eiji Harata

IPC分类号： A61K31/728 ,  A61K9/00 ,  A61K31/4704 ,  A61K31/7084 ,  A61P27/04

CPC分类号： A61K9/0048 ,  A61K31/4704 ,  A61K31/7084 ,  A61K31/728 ,  A61P27/04

摘要： Provided are an ocular surface drug-retaining agent that enables an excellent improvement in retainability of a medicament on an ocular surface and an eye drop containing the agent. An ocular surface drug-retaining agent containing a copolymer having three different kinds of constituent units at a specific ratio can express an excellent effect of retaining a medicament on an ocular surface (in particular, a corneal surface) to allow the effect or action of the drug to be sustained over a long period of time.

公开(公告)号：US20240299443A1

公开(公告)日：2024-09-12

申请号：US18039129

申请日：2021-11-24

申请人： KINKI UNIVERSITY ,  NOF CORPORATION

发明人： Noriaki NAGAI ,  Ryotaro SEIRIKI ,  Misa MINAMI ,  Shunsuke SAKURAI ,  Eiji HARATA

IPC分类号： A61K31/80 ,  A61P27/04

CPC分类号： A61K31/80 ,  A61P27/04

摘要： A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %:




wherein R1 to R6 are as defined herein.

公开(公告)号：US20240293601A1

公开(公告)日：2024-09-05

申请号：US18569841

申请日：2022-06-17

申请人： KINKI UNIVERSITY ,  GUNZE LIMITED

发明人： Noritaka ISOGAI ,  Takeshi TERAMURA ,  Kazunari MASUTANI ,  Hiroshi MITACHI ,  Takatoshi YOTSUYANAGI

IPC分类号： A61L27/58 ,  A61F2/50 ,  A61L27/38

CPC分类号： A61L27/58 ,  A61F2/50 ,  A61L27/3817 ,  A61L2430/14

摘要： A skeletal structure for an artificial pinna includes a base portion formed in a flat shape with a fibrous structural body using a bioabsorbable material, and a helix portion and an antihelix portion disposed on the front surface of the base portion. In the skeletal structure, the base portion is provided with a two-dimensional elastic structure, and the helix portion and the antihelix portion are provided with a three-dimensional fiber structure formed with the fibrous structural bodies. Thus, a flexible skeletal structure can be provided.

公开(公告)号：US11951231B2

公开(公告)日：2024-04-09

申请号：US16966226

申请日：2019-01-31

申请人： NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY ,  KINKI UNIVERSITY ,  FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

发明人： Takashi Yurube ,  Yoshiki Takeoka ,  Koichi Morimoto ,  Saori Kunii ,  Kaoru Omae

IPC分类号： A61L27/24 ,  A61K38/39 ,  A61L27/50 ,  A61L27/52 ,  A61L27/54 ,  A61P19/08 ,  A61P43/00 ,  C07K1/12 ,  C07K14/78 ,  C12M1/00 ,  C12N5/00 ,  C12N5/077

CPC分类号： A61L27/24 ,  A61L27/50 ,  A61L27/52 ,  C07K14/78 ,  C12N5/0655

摘要： A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.

公开(公告)号：US20210323930A1

公开(公告)日：2021-10-21

申请号：US16479674

申请日：2018-01-22

申请人： Nippon Chemiphar Co., Ltd. ,  Kinki University

发明人： Hiroto Tanaka ,  Isao Ooi ,  Kohei Hayashida ,  Toru Ogawa ,  Atsufumi Kawabata

IPC分类号： C07D235/16 ,  C07D403/12 ,  C07D401/12 ,  C07D403/08 ,  C07D401/14 ,  A61P29/00

摘要： A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; m represents 0, 1, or 2; and n represents 0 or 1.

公开(公告)号：US20210127687A1

公开(公告)日：2021-05-06

申请号：US16491956

申请日：2018-03-02

申请人： RILIS CO., LTD. ,  KINKI UNIVERSITY

发明人： Atsushi HENMI ,  Masato NOMURA

IPC分类号： A01N65/34 ,  A01N37/10 ,  A01N35/04 ,  A01N65/08 ,  A61L9/013 ,  A61L9/01

摘要： To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.

公开(公告)号：US20190381120A1

公开(公告)日：2019-12-19

申请号：US16470811

申请日：2017-12-19

申请人： KINKI UNIVERSITY ,  KOBAYASHI PHARMACEUTICAL CO., LTD.

发明人： Shozo NISHIDA ,  Masanobu TSUBAKI ,  Tomoya TAKEDA ,  Kiyotaka OKUNO ,  Satoshi WACHI

IPC分类号： A61K36/07 ,  A61K9/00 ,  A61P25/02 ,  A61P35/00 ,  A61K31/381 ,  A61K31/4965 ,  A61K31/4748 ,  A61K31/337 ,  A61K33/243

摘要： No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin.A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

公开(公告)号：US09828406B2

公开(公告)日：2017-11-28

申请号：US14122308

申请日：2012-05-28

申请人： Reiko Sugiura ,  Osamu Muraoka ,  Nozomi Tsutsui ,  Ayako Kita ,  Tatsuki Kunoh

发明人： Reiko Sugiura ,  Osamu Muraoka ,  Nozomi Tsutsui ,  Ayako Kita ,  Tatsuki Kunoh

IPC分类号： C07H13/06 ,  A61K31/7012 ,  A61K31/7032 ,  A61K45/06

CPC分类号： C07H13/06 ,  A61K31/7012 ,  A61K31/7032 ,  A61K45/06 ,  A61K2300/00

摘要： The invention is intended to provide an excellent antitumor agent. An antitumor agent contains a glycolipid glycoside compound represented by Formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: in the formula, R1 to R4 are the same as or different from each other and represent an alkanoyl group or a hydrogen atom, and A represents a sugar alcohol residue or a polyol residue.

公开(公告)号：US20160121152A1

公开(公告)日：2016-05-05

申请号：US14899024

申请日：2014-06-18

申请人： TAMURA TECO CO., LTD. ,  KINKI UNIVERSITY

发明人： Kozo Tamura ,  Yoshiyuki Fukuda ,  Shunji Ishiwata ,  Atsushi Taga

IPC分类号： A62D3/38

CPC分类号： A62D3/38 ,  A62D2101/22 ,  A62D2101/26 ,  A62D2101/28

摘要： There are provided an anticancer agent degradation method for protecting medical professionals from exposure to an anticancer agent externally scattered in, for example, a safety cabinet or prescription laboratory, during drug preparation or other circumstance, and an anticancer agent degradation apparatus for use with this anticancer agent degradation method. Anticancer agent flyoff in a safety cabinet, etc. is degraded by exploiting an action of ozone-containing air humidified by humidifying means. A relative humidity of humidified ozone-containing air is preferably greater than or equal to 80%. In controlling degradation treatment on the basis of CT values, a difference between expected humidity and measured humidity is reflected in an increment of CT value to understand the progress of anticancer agent degradation properly.

摘要翻译： 提供了一种抗癌剂降解方法，用于在药物制备或其他情况下，保护医学专业人员免受外部分散在例如安全柜或处方实验室中的抗癌剂，以及与该抗癌剂一起使用的抗癌剂降解装置 代理降解法。 通过利用由加湿装置加湿的含臭氧空气的作用，安全柜等中的抗癌剂飞行降解。 加湿的含臭氧空气的相对湿度优选为大于或等于80％。 在根据CT值控制降解处理中，预期湿度和测量湿度之间的差异反映在CT值的增加中，以正确理解抗癌剂降解的进展。

公开(公告)号：US20140348797A1

公开(公告)日：2014-11-27

申请号：US14344365

申请日：2011-12-16

申请人： Takashi Ano ,  Yoichiro Hirose

发明人： Takashi Ano ,  Yoichiro Hirose

IPC分类号： A01N63/00

CPC分类号： A01N63/00 ,  C12N1/20 ,  C12R1/01

摘要： To provide a method for inhibiting the proliferation of a plant pathogenic bacterium. A method for inhibiting the proliferation of a plant pathogenic bacterium, including culturing a microorganism having an ability to inhibit the proliferation of a plant pathogenic bacterium and belonging to the genus Collimonas, and seeding the cultured microorganism to a plant soil.

摘要翻译： 提供抑制植物致病菌增殖的方法。 一种抑制植物致病菌的增殖的方法，包括培养具有抑制植物致病菌的增殖并属于菌落的属性的微生物，并将培养的微生物接种到植物土壤中。